Development of a low-cost, clinical-grade iPS maintenance medium for enabling stem cell therapy manufacturing

  • Post author:
  • Post category:

Translational Candidate HiDef-B8, an iPS cell maintenance medium designed to reduce stem cell GMP manufacturing costs and risk. Area of Impact HiDef-B8 addresses scale-up manufacturing, by being lower-cost ($300/L) and…

Continue ReadingDevelopment of a low-cost, clinical-grade iPS maintenance medium for enabling stem cell therapy manufacturing